EryDel Raises Euro 26.5 Million in Financing
EryDel Appoints Guenter R Janhofer, MD, as Chief Medical Officer
Urbino, Italy – February 16, 2018 - EryDel SpA (www.erydel.com), a clinical stage biopharmaceutical company specialized in the development of drugs and diagnostics delivered through autologous red blood cells, today announced the appointment of Guenter Reinhold Janhofer, MD, to the position of Chief Medical Officer
EryDel announced the initiation of the Ataxia Telangiectasia Trial with the EryDex System (ATTEST) study
EryDel Consortium gains Euro 6 million Funding for development of EDS for the treatment of Ataxia Telangiectasia
Long term benefit of erytrocyte-delivered dexamathasone in Ataxia Telangiectasia
EryDel expands Series B financing to 29.5M
Phase II results in Ataxia Telangiectasia published in Orphanet Journal of Rare Diseases
EryDel selected as one of the top five candidates in 2013 EuropaBio Most Innovative EU Biotech SME Award
Enzyme-loaded erythrocytes restore normal blood concentrations of Phenylalanine in a mouse model of Phenylketonuria (PKU)
EryDel SpA Completes €15 Million Series B financing
EryDel SpA Announces EMA Orphan Drug Designation for EryDex for the treatment of Ataxia Telangiectasia
The Stainig procedures brochure, is now availables for downloading in the Documents section.
The Injectable Saline Adaptor for EryKit_01 Instruction For Use - all languages - is now available for downloading in the Documents section.